Emergent BioSolutions Inc
Change company Symbol lookup
Select an option...
EBS Emergent BioSolutions Inc
HBI HanesBrands Inc
BAC Bank of America Corp
RYB RYB Education Inc
RETA Reata Pharmaceuticals Inc
RDFN Redfin Corp
RCUS Arcus Biosciences Inc
RBWNY Koninklijke Boskalis Westminster NV
RBII Rising Biosciences Inc
RAD Rite Aid Corp
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Closing Price
$83.49
Day's Change
1.51 (1.84%)
Bid
--
Ask
--
B/A Size
--
Day's High
83.63
Day's Low
81.06
Volume
(Average)
Volume:
493,198

10-day average volume:
477,563
493,198

Company Profile

Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Valuation Ratios

Price/Earnings (TTM)
64.47x
Price/Sales (TTM)
3.95x
Price/Book (MRQ)
4.06x
Price/Cash Flow (TTM)
24.26x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

May 2020
Current Month
2.4M
Previous Month
2.3M
Percent of Float
5.60%
Days to Cover
5.0001 Days

Share Information

EBS is in a share class of common stock
Float
44.5M
Shares Outstanding
52.4M
Institutions Holding Shares
359
86.72%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Fuad El-HibriChmn.
  • Robert G. KramerPres.
  • Richard S. LindahlCFO
  • Katherine Strei
  • Atul SaranExec.VP

Address

Insider Trading

During the most recent quarter, 534K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.